Concepts (193)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Kidney Transplantation | 6 | 2018 | 755 | 0.880 |
Why?
|
| Transplant Recipients | 2 | 2018 | 324 | 0.620 |
Why?
|
| Ontario | 10 | 2020 | 98 | 0.520 |
Why?
|
| Acute Kidney Injury | 6 | 2020 | 739 | 0.490 |
Why?
|
| Living Donors | 2 | 2018 | 171 | 0.460 |
Why?
|
| NF-kappa B | 4 | 2010 | 1549 | 0.440 |
Why?
|
| Placebos | 1 | 2011 | 437 | 0.380 |
Why?
|
| Breast Neoplasms | 8 | 2019 | 15694 | 0.360 |
Why?
|
| Cardiovascular Diseases | 2 | 2017 | 2195 | 0.360 |
Why?
|
| Truth Disclosure | 1 | 2011 | 180 | 0.350 |
Why?
|
| Mastectomy | 4 | 2015 | 1534 | 0.350 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2015 | 2231 | 0.350 |
Why?
|
| Clavicle | 1 | 2009 | 65 | 0.340 |
Why?
|
| Patients | 1 | 2011 | 245 | 0.340 |
Why?
|
| Lymphatic Irradiation | 1 | 2009 | 133 | 0.330 |
Why?
|
| Kidney Failure, Chronic | 5 | 2019 | 960 | 0.330 |
Why?
|
| Research Design | 2 | 2011 | 1544 | 0.290 |
Why?
|
| Spinal Neoplasms | 1 | 2012 | 631 | 0.290 |
Why?
|
| Glomerular Filtration Rate | 3 | 2020 | 602 | 0.280 |
Why?
|
| Cause of Death | 3 | 2019 | 752 | 0.280 |
Why?
|
| Creatinine | 5 | 2020 | 531 | 0.280 |
Why?
|
| Plants | 1 | 2005 | 62 | 0.260 |
Why?
|
| Hypertension | 2 | 2020 | 1503 | 0.260 |
Why?
|
| Neoadjuvant Therapy | 3 | 2015 | 4975 | 0.260 |
Why?
|
| Nephrectomy | 2 | 2018 | 779 | 0.260 |
Why?
|
| Clinical Trials as Topic | 2 | 2015 | 3719 | 0.260 |
Why?
|
| Phenols | 1 | 2005 | 107 | 0.260 |
Why?
|
| Risk Assessment | 8 | 2020 | 6869 | 0.250 |
Why?
|
| Flavonoids | 1 | 2005 | 188 | 0.250 |
Why?
|
| Renal Dialysis | 4 | 2019 | 945 | 0.240 |
Why?
|
| Radiosurgery | 1 | 2012 | 1330 | 0.220 |
Why?
|
| Arteriovenous Shunt, Surgical | 2 | 2015 | 112 | 0.210 |
Why?
|
| Cardiac Surgical Procedures | 3 | 2017 | 1237 | 0.190 |
Why?
|
| Age Factors | 6 | 2019 | 5377 | 0.190 |
Why?
|
| Long Term Adverse Effects | 1 | 2020 | 23 | 0.180 |
Why?
|
| Kidney | 2 | 2020 | 2146 | 0.180 |
Why?
|
| Renin-Angiotensin System | 1 | 2020 | 103 | 0.180 |
Why?
|
| Proportional Hazards Models | 6 | 2020 | 4988 | 0.180 |
Why?
|
| Potassium | 1 | 2020 | 329 | 0.170 |
Why?
|
| Hyperkalemia | 1 | 2020 | 79 | 0.170 |
Why?
|
| Kidney Diseases | 2 | 2017 | 691 | 0.170 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 2020 | 151 | 0.170 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2010 | 1833 | 0.170 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2020 | 257 | 0.160 |
Why?
|
| Drug Monitoring | 1 | 2020 | 333 | 0.160 |
Why?
|
| Neoplasm Proteins | 1 | 2010 | 3230 | 0.160 |
Why?
|
| Risk Factors | 10 | 2020 | 17523 | 0.160 |
Why?
|
| Curcumin | 1 | 2018 | 117 | 0.160 |
Why?
|
| Reactive Oxygen Species | 1 | 2002 | 987 | 0.150 |
Why?
|
| Time Factors | 7 | 2020 | 12926 | 0.150 |
Why?
|
| Aged | 17 | 2020 | 70117 | 0.150 |
Why?
|
| Female | 23 | 2020 | 141928 | 0.150 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2002 | 1538 | 0.150 |
Why?
|
| Biomarkers | 7 | 2020 | 5047 | 0.150 |
Why?
|
| Albuminuria | 1 | 2017 | 113 | 0.150 |
Why?
|
| Retrospective Studies | 12 | 2020 | 37905 | 0.150 |
Why?
|
| Incidence | 5 | 2019 | 5673 | 0.140 |
Why?
|
| Recovery of Function | 1 | 2020 | 703 | 0.140 |
Why?
|
| Middle Aged | 18 | 2020 | 86204 | 0.140 |
Why?
|
| Adult | 15 | 2020 | 77950 | 0.140 |
Why?
|
| Chemokine CCL2 | 1 | 2017 | 203 | 0.140 |
Why?
|
| Neoplasm Recurrence, Local | 4 | 2012 | 10035 | 0.140 |
Why?
|
| Humans | 30 | 2020 | 261506 | 0.130 |
Why?
|
| Tissue and Organ Procurement | 1 | 2018 | 233 | 0.130 |
Why?
|
| Prognosis | 9 | 2020 | 21713 | 0.130 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2018 | 521 | 0.130 |
Why?
|
| Follow-Up Studies | 9 | 2020 | 14889 | 0.130 |
Why?
|
| Aortic Aneurysm, Abdominal | 1 | 2018 | 384 | 0.120 |
Why?
|
| Doxorubicin | 3 | 2007 | 3005 | 0.120 |
Why?
|
| Graft Rejection | 2 | 2018 | 834 | 0.120 |
Why?
|
| Chemotherapy, Adjuvant | 4 | 2007 | 3890 | 0.120 |
Why?
|
| Antineoplastic Agents | 4 | 2011 | 14289 | 0.120 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2010 | 5437 | 0.120 |
Why?
|
| Postoperative Complications | 3 | 2018 | 5542 | 0.120 |
Why?
|
| Postoperative Hemorrhage | 1 | 2015 | 162 | 0.110 |
Why?
|
| Databases, Factual | 2 | 2019 | 2218 | 0.110 |
Why?
|
| Lymphatic Metastasis | 3 | 2009 | 4844 | 0.110 |
Why?
|
| Prospective Studies | 8 | 2020 | 12873 | 0.110 |
Why?
|
| Heart Diseases | 2 | 2017 | 732 | 0.110 |
Why?
|
| Cystatin C | 1 | 2013 | 54 | 0.110 |
Why?
|
| Comorbidity | 2 | 2017 | 2352 | 0.110 |
Why?
|
| Radiotherapy Dosage | 2 | 2012 | 3842 | 0.110 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2015 | 340 | 0.100 |
Why?
|
| Consent Forms | 1 | 2011 | 25 | 0.100 |
Why?
|
| Placebo Effect | 1 | 2011 | 39 | 0.100 |
Why?
|
| Canada | 3 | 2019 | 429 | 0.100 |
Why?
|
| Treatment Outcome | 9 | 2020 | 32848 | 0.100 |
Why?
|
| Unnecessary Procedures | 1 | 2012 | 104 | 0.100 |
Why?
|
| Atrial Fibrillation | 1 | 2017 | 719 | 0.090 |
Why?
|
| Male | 15 | 2020 | 123000 | 0.090 |
Why?
|
| Signal Transduction | 3 | 2005 | 11965 | 0.090 |
Why?
|
| Survival Analysis | 4 | 2019 | 9180 | 0.080 |
Why?
|
| Combined Modality Therapy | 2 | 2015 | 8865 | 0.080 |
Why?
|
| Cervix Uteri | 1 | 2010 | 253 | 0.080 |
Why?
|
| Postoperative Period | 2 | 2013 | 665 | 0.080 |
Why?
|
| Predictive Value of Tests | 3 | 2020 | 4892 | 0.080 |
Why?
|
| Medical Records Systems, Computerized | 1 | 2008 | 220 | 0.070 |
Why?
|
| Patient Education as Topic | 1 | 2011 | 748 | 0.070 |
Why?
|
| Survival Rate | 3 | 2017 | 12221 | 0.070 |
Why?
|
| Neoplasms | 2 | 2019 | 15193 | 0.070 |
Why?
|
| Axilla | 1 | 2009 | 902 | 0.070 |
Why?
|
| Sex Factors | 3 | 2019 | 2139 | 0.070 |
Why?
|
| Polyphenols | 1 | 2005 | 29 | 0.070 |
Why?
|
| Multivariate Analysis | 3 | 2018 | 4298 | 0.060 |
Why?
|
| Caregivers | 1 | 2011 | 677 | 0.060 |
Why?
|
| Radiography | 1 | 2009 | 1904 | 0.060 |
Why?
|
| Cohort Studies | 4 | 2020 | 9244 | 0.060 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2011 | 1209 | 0.060 |
Why?
|
| Pilot Projects | 1 | 2010 | 2803 | 0.060 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2012 | 1303 | 0.060 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2002 | 184 | 0.050 |
Why?
|
| Aged, 80 and over | 6 | 2020 | 29902 | 0.050 |
Why?
|
| Neoplasm Staging | 3 | 2007 | 13658 | 0.050 |
Why?
|
| Biopsy | 1 | 2010 | 3443 | 0.050 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2009 | 1648 | 0.050 |
Why?
|
| Chi-Square Distribution | 2 | 2017 | 1323 | 0.050 |
Why?
|
| Body Mass Index | 1 | 2009 | 2203 | 0.050 |
Why?
|
| Lymph Node Excision | 1 | 2009 | 1959 | 0.050 |
Why?
|
| Odds Ratio | 2 | 2017 | 2316 | 0.050 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2005 | 5178 | 0.050 |
Why?
|
| California | 1 | 2020 | 208 | 0.050 |
Why?
|
| Tamoxifen | 1 | 2004 | 876 | 0.050 |
Why?
|
| Young Adult | 5 | 2020 | 21445 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2005 | 1493 | 0.040 |
Why?
|
| Natriuretic Peptide, C-Type | 1 | 2018 | 16 | 0.040 |
Why?
|
| Hospitalization | 2 | 2020 | 2083 | 0.040 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 1 | 2009 | 2370 | 0.040 |
Why?
|
| Interleukin-18 | 1 | 2018 | 100 | 0.040 |
Why?
|
| Lymph Nodes | 1 | 2009 | 2967 | 0.040 |
Why?
|
| Australia | 1 | 2018 | 225 | 0.040 |
Why?
|
| Elective Surgical Procedures | 1 | 2018 | 250 | 0.040 |
Why?
|
| Patient Selection | 2 | 2018 | 2055 | 0.040 |
Why?
|
| Quality of Life | 1 | 2011 | 4532 | 0.040 |
Why?
|
| Internationality | 1 | 2018 | 208 | 0.040 |
Why?
|
| Confidence Intervals | 1 | 2018 | 756 | 0.040 |
Why?
|
| Cell Survival | 1 | 2002 | 3045 | 0.030 |
Why?
|
| Radiotherapy | 1 | 2003 | 1824 | 0.030 |
Why?
|
| Preoperative Period | 1 | 2017 | 344 | 0.030 |
Why?
|
| Esophageal Neoplasms | 2 | 2009 | 3168 | 0.030 |
Why?
|
| United States | 3 | 2020 | 15433 | 0.030 |
Why?
|
| C-Reactive Protein | 1 | 2018 | 527 | 0.030 |
Why?
|
| Decision Support Techniques | 1 | 2020 | 622 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2018 | 1544 | 0.030 |
Why?
|
| Hodgkin Disease | 1 | 2003 | 1429 | 0.030 |
Why?
|
| Radiotherapy, Intensity-Modulated | 1 | 2005 | 2104 | 0.030 |
Why?
|
| Perioperative Care | 1 | 2018 | 451 | 0.030 |
Why?
|
| Graft Survival | 1 | 2018 | 1062 | 0.030 |
Why?
|
| Subarachnoid Hemorrhage | 1 | 2015 | 95 | 0.030 |
Why?
|
| Adolescent | 4 | 2020 | 31252 | 0.030 |
Why?
|
| Cerebral Hemorrhage | 1 | 2015 | 183 | 0.030 |
Why?
|
| Models, Biological | 1 | 2002 | 3254 | 0.030 |
Why?
|
| Disease Progression | 2 | 2017 | 6682 | 0.030 |
Why?
|
| Double-Blind Method | 1 | 2018 | 2588 | 0.030 |
Why?
|
| Kidney Function Tests | 1 | 2013 | 192 | 0.030 |
Why?
|
| Propensity Score | 1 | 2015 | 750 | 0.030 |
Why?
|
| Likelihood Functions | 1 | 2012 | 233 | 0.020 |
Why?
|
| Time | 1 | 2010 | 178 | 0.020 |
Why?
|
| Animals | 2 | 2005 | 59536 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2019 | 6207 | 0.020 |
Why?
|
| Perception | 1 | 2011 | 350 | 0.020 |
Why?
|
| Apoptosis | 1 | 2002 | 7591 | 0.020 |
Why?
|
| Data Interpretation, Statistical | 1 | 2010 | 482 | 0.020 |
Why?
|
| Reference Standards | 1 | 2009 | 339 | 0.020 |
Why?
|
| Data Collection | 1 | 2010 | 620 | 0.020 |
Why?
|
| Guideline Adherence | 1 | 2012 | 636 | 0.020 |
Why?
|
| Uncertainty | 1 | 2009 | 320 | 0.020 |
Why?
|
| Radiography, Thoracic | 1 | 2009 | 462 | 0.020 |
Why?
|
| Child, Preschool | 2 | 2013 | 16273 | 0.020 |
Why?
|
| bcl-2-Associated X Protein | 1 | 2005 | 367 | 0.020 |
Why?
|
| Kidney Neoplasms | 1 | 2019 | 3022 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2015 | 6100 | 0.020 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2005 | 726 | 0.020 |
Why?
|
| Cytoplasm | 1 | 2005 | 652 | 0.010 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2005 | 15862 | 0.010 |
Why?
|
| Colorectal Neoplasms | 1 | 2019 | 3578 | 0.010 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2011 | 2594 | 0.010 |
Why?
|
| Practice Guidelines as Topic | 1 | 2012 | 2403 | 0.010 |
Why?
|
| Pancreatic Neoplasms | 1 | 2019 | 5061 | 0.010 |
Why?
|
| Fluorouracil | 1 | 2005 | 1944 | 0.010 |
Why?
|
| Cross-Sectional Studies | 1 | 2011 | 4314 | 0.010 |
Why?
|
| Child | 2 | 2013 | 29154 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2009 | 4971 | 0.010 |
Why?
|
| Cell Nucleus | 1 | 2005 | 1620 | 0.010 |
Why?
|
| Protein Kinases | 1 | 2003 | 874 | 0.010 |
Why?
|
| Surveys and Questionnaires | 1 | 2011 | 5687 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2009 | 6009 | 0.010 |
Why?
|
| Cyclophosphamide | 1 | 2005 | 3001 | 0.010 |
Why?
|
| Algorithms | 1 | 2009 | 3890 | 0.010 |
Why?
|
| B-Lymphocytes | 1 | 2003 | 1294 | 0.010 |
Why?
|
| Lung Neoplasms | 1 | 2019 | 11538 | 0.010 |
Why?
|
| Infant | 1 | 2010 | 13310 | 0.010 |
Why?
|
| Inflammation | 1 | 2003 | 2522 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2009 | 7551 | 0.010 |
Why?
|